This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Mirodenafil
- DrugBank Accession Number
- DB11792
- Background
Mirodenafil has been used in trials studying the treatment and supportive care of Kidney Diseases, Urologic Diseases, Renal Insufficiency, Erectile Dysfunction, and Male Erectile Dysfunction.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Mirodenafil (DB11792)
- Weight
- Average: 531.67
Monoisotopic: 531.251540485 - Chemical Formula
- C26H37N5O5S
- Synonyms
- Mirodenafil
- External IDs
- SK-3530
- SK3530
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of hypotension can be increased when Mirodenafil is combined with Abaloparatide. Acebutolol Mirodenafil may increase the antihypertensive activities of Acebutolol. Aldesleukin The risk or severity of hypotension can be increased when Mirodenafil is combined with Aldesleukin. Alfuzosin The risk or severity of hypotension and syncope can be increased when Mirodenafil is combined with Alfuzosin. Aliskiren Mirodenafil may increase the antihypertensive activities of Aliskiren. Alprostadil The risk or severity of hypotension and priapism can be increased when Mirodenafil is combined with Alprostadil. Ambrisentan Mirodenafil may increase the antihypertensive activities of Ambrisentan. Amifostine The risk or severity of hypotension can be increased when Mirodenafil is combined with Amifostine. Amiloride The risk or severity of hypotension can be increased when Mirodenafil is combined with Amiloride. Amiodarone The risk or severity of hypotension can be increased when Mirodenafil is combined with Amiodarone. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Benzenesulfonamides
- Alternative Parents
- Benzenesulfonyl compounds / Pyrrolopyrimidines / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / N-alkylpiperazines / Pyrimidones / Organosulfonamides / Substituted pyrroles / Sulfonyls show 9 more
- Substituents
- 1,2-aminoalcohol / 1,4-diazinane / Alcohol / Alkanolamine / Alkyl aryl ether / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenesulfonamide / Benzenesulfonyl group show 28 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 504G362H0H
- CAS number
- 862189-95-5
- InChI Key
- MIJFNYMSCFYZNY-UHFFFAOYSA-N
- InChI
- InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)
- IUPAC Name
- 5-ethyl-2-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl}-2-propoxyphenyl)-7-propyl-3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one
- SMILES
- CCCOC1=CC=C(C=C1C1=NC2=C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 12001014
- PubChem Substance
- 347828141
- ChemSpider
- 10173481
- ZINC
- ZINC000035077050
- Wikipedia
- Mirodenafil
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Erectile Dysfunction 2 2 Terminated Treatment Erectile Dysfunction 1 1 Completed Supportive Care Impaired Renal Function / Kidney Diseases / Urological Diseases 1 1 Completed Treatment Drug Interaction Potentiation 2 1 Completed Treatment Erectile Dysfunction 3 Not Available Terminated Not Available Erectile Dysfunction 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.181 mg/mL ALOGPS logP 2.85 ALOGPS logP 2.44 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 7.69 Chemaxon pKa (Strongest Basic) 5.83 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 116.47 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 146.61 m3·mol-1 Chemaxon Polarizability 57.75 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Enzymes
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Components:
Drug created at October 20, 2016 20:48 / Updated at February 21, 2021 18:53